for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Hualan Biological Engineering Inc

002007.SZ

Latest Trade

33.40CNY

Change

0.03(+0.09%)

Volume

5,959,370

Today's Range

33.22

 - 

33.52

52 Week Range

19.74

 - 

38.53

As of on the Shenzhen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
33.37
Open
33.44
Volume
5,959,370
3M AVG Volume
250.52
Today's High
33.52
Today's Low
33.22
52 Week High
38.53
52 Week Low
19.74
Shares Out (MIL)
1,403.06
Market Cap (MIL)
46,862.17
Forward P/E
32.90
Dividend (Yield %)
0.80

Latest Developments

More

Hualan Biological Engineering's H1 Net Profit Up 11.9% Y/Y

Hualan Biological Engineering Elects Chairman

Hualan Biological Engineering's 2018 Net Profit Up 38.8 Pct Y/Y

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Hualan Biological Engineering Inc

HUALAN BIOLOGICAL ENGINEERING, INC. is a China-based company principally engaged in the research, development, production and sales of blood products. It also produces vaccine products and biological engineering products. The Company's main products include human albumins, human immunoglobulin for intravenous injection, human immunoglobulin, human coagulation factors, human rabies immunoglobulin, human tetanus immunoglobulin and influenza vaccines, among others. The Company mainly operates its businesses in domestic markets.

Industry

Biotechnology & Drugs

Contact Info

No.A1, Hualan Avenue

+86.373.3559989

http://english.hualanbio.com

Executive Leadership

Kang An

Chairman of the Board, General Manager

Junmin Xie

Chief Financial Officer, Secretary of the Board

Bei Fan

Executive Deputy General Manager, Director

Ruowen Pan

Deputy General Manager, Director

Qiping Wang

Deputy General Manager, Director

Key Stats

1.82 mean rating - 22 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2016

1.9K

2017

2.4K

2018

3.2K

2019(E)

4.1K
EPS (CNY)

2016

1.258

2017

1.323

2018

0.817

2019(E)

1.015
Price To Earnings (TTM)
34.82
Price To Sales (TTM)
12.27
Price To Book (MRQ)
7.53
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
25.72
Return on Equity (TTM)
22.60

Latest News

Latest News

REFILE-BRIEF-Hualan Biological Engineering Says Q3 Net Profit Up 63.15 Percent Y/Y

* SAYS Q3 NET PROFIT UP 63.15 PERCENT Y/Y Source text in Chinese: https://bit.ly/2CNvGUn Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Hualan Biological Engineering to pay cash dividend of 3 yuan (pre-tax) for every 10 shares

* Says it plans to pay a cash dividend of 3 yuan (pre-tax) for every 10 shares as the dividend payment plan for 2017

BRIEF-Hualan Biological Engineering Says 2017 Net Profit Up 5.2 Percent Y/Y

* SAYS 2017 NET PROFIT UP 5.2 PERCENT Y/Y Source text in Chinese: https://bit.ly/2I4DVuu Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Hualan Biological Engineering's Prelim 2017 Net Profit Up 5.2 Pct Y/Y

* SAYS PRELIM 2017 NET PROFIT UP 5.2 PERCENT Y/Y AT 820.8 MILLION YUAN ($130.02 million) Source text in Chinese: http://bit.ly/2F7RVG5 Further company coverage: ($1 = 6.3130 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Hualan Biological Engineering obtains high-tech enterprise recognition

* Says it will enjoy tax preference of 15 percent for three years from Aug. 29, 2017

BRIEF-Hualan Biological Engineering's 9-month net profit up 1.9 pct y/y

* Says 9-month net profit up 1.9 percent y/y at 619.1 million yuan ($93.49 million)

BRIEF-Hualan Biological Engineering unit passes GMP recognition

* Says Chongqing-based biotechnology unit passed goods manufacture practice (GMP)recognition for human immune globulin manufactured by the company

BRIEF-Hualan Biological Engineering sees H1 net profit up by as much as 15 pct y/y

* Says it sees H1 net profit to rise up to 15 percent y/y to 410.3-471.9 million yuan ($60.34-$69.40 million)

BRIEF-Hualan Biological Engineering says dividend payment date

* Says it will pay a cash dividend of 4 yuan per 10 shares (before tax) for 2016 to shareholders of record on June 12

BRIEF-Hualan Biological Engineering sees H1 FY 2017 net profit to up 20 pct to 35 pct

* Sees H1 FY 2017 net profit to increase by 20 percent to 35 percent, or to be 492.4 million yuan to 553.9 million yuan

BRIEF-Hualan Biological Engineering's Q1 net profit up 32.7 pct y/y

* Says Q1 net profit up 32.7 percent y/y at 255.3 million yuan ($37.05 million)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up